INVESCO Ltd (IVZ)

Hopefully, a recession is averted, but if one arrives, the Invesco S&P 500 High Dividend Low Volatility ETF could help investors weather the storm.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

There are signs that the market could see a big pullback.

Past returns aren't guaranteed to repeat, but investors could still see huge upside.

Both funds are built on the same market leaders. The difference is how much -- and what gets left out.

Vanguard's ultra-low 0.06% expense ratio appeals to cost-conscious investors, while Invesco's small-cap strategy delivered 22.3% returns over the past year.

PPA targets legacy hardware with broader industrial exposure and stronger one-year returns, while SHLD emphasizes emerging tech and cybersecurity at lower cost.

PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.

SpaceX's Nasdaq-100 weighting will more than double at the Sept. 18 rebalance as lockup expirations expand its float, forcing index funds to buy billions in shares.

One fund concentrates on solar alone, while the other diversifies across wind and other renewables. Which strategy aligns with your risk tolerance?

PPH offers concentrated pharma exposure with 1.9% yield and lower volatility, while RSPH provides broader diversification across 60 healthcare holdings.

The market remains historically concentrated in tech, but the broader rotation away from that sector continues.

Invesco’s 33.6% return over the past six months has outpaced the S&P 500 by 20.8%, and its stock price has climbed to $31.99 per share. This was partly thank...

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.

VOO and QQQM provide instant diversification and long-term safety.

IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.

Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.

High-growth holdings have driven this fund's success.

It has outperformed the S&P 500 and the Nasdaq 100 over the past five years.

Could IPO lockup expirations create buying opportunities for long-term investors?

Investors who focus on growth in their younger years could build significant wealth by the time they reach retirement.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.